Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31133216 | 0.83 | PIK3CA (0.34) | PIK3CAPIK3CDPIK3CBDRD4DRD3 | |
| SCHEMBL24149172 | 0.77 | PIK3CA (0.44) | PIK3CAPIK3CDPIK3CBEIF4A3 | |
| SCHEMBL25157402 | 0.76 | DRD3 (0.65) | DRD4DRD3 | |
| SCHEMBL16629843 | 0.76 | PSEN1 (0.45) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL31133168 | 0.75 | PIK3CA (0.34) | PIK3CAPIK3CDPIK3CB | |
| SCHEMBL3077903 | 0.73 | NPC1 (0.47) | PIK3CAPIK3CDPIK3CBEIF4A3 | |
| SCHEMBL23685723 | 0.73 | EPHB3 (0.44) | PIK3CAPIK3CDPIK3CBEIF4A3 | |
| SCHEMBL3074755 | 0.73 | SMN1; SMN2 (0.46) | — | |
| SCHEMBL21730212 | 0.73 | PIK3CA (0.36) | PIK3CAPIK3CDPIK3CBKMOEIF4A3 | |
| SCHEMBL15951734 | 0.73 | PIK3CA (0.36) | PIK3CAPIK3CDPIK3CBKMOEIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| CN-115181092-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-112279837-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-111747954-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-112279837-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| CN-112055709-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| CN-111747954-A | Pyrazine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | PIK3CA 161/4885PIK3CD 393/4885PIK3CB 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.